PT - JOURNAL ARTICLE AU - Briggs, Jessica AU - Takahashi, Saki AU - Nayebare, Patience AU - Cuu, Gloria AU - Rek, John AU - Zedi, Maato AU - Kizza, Timothy AU - Arinaitwe, Emmanuel AU - Nankabirwa, Joaniter I. AU - Kamya, Moses AU - Jagannathan, Prasanna AU - Jacobson, Karen AU - Rosenthal, Philip J. AU - Dorsey, Grant AU - Greenhouse, Bryan AU - Ssewanyana, Isaac AU - Rodríguez-Barraquer, Isabel TI - Reconstructing the SARS-CoV-2 epidemic in eastern Uganda through longitudinal serosurveillance in a malaria cohort AID - 10.1101/2022.09.20.22280170 DP - 2022 Jan 01 TA - medRxiv PG - 2022.09.20.22280170 4099 - http://medrxiv.org/content/early/2022/09/21/2022.09.20.22280170.short 4100 - http://medrxiv.org/content/early/2022/09/21/2022.09.20.22280170.full AB - Importance Estimating the true burden of SARS-CoV-2 infection has been difficult in sub-Saharan Africa due to asymptomatic infections and inadequate testing capacity. Antibody responses from serologic surveys can provide an estimate of SARS-CoV-2 exposure at the population level.Objective To estimate SARS-CoV-2 seroprevalence, attack rates, and re-infection in eastern Uganda using serologic surveillance from 2020 to early 2022.Design Plasma samples from participants in the Program for Resistance, Immunology, Surveillance, and Modeling of Malaria in Uganda (PRISM) Border Cohort were obtained at four sampling intervals: October-November 2020; March-April 2021; August-September 2021; and February-March 2022. Setting: Tororo and Busia districts, Uganda.Participants 1,483 samples from 441 participants living in 76 households were tested. Each participant contributed up to 4 time points for SARS-CoV-2 serology, with almost half of all participants contributing at all 4 time points, and almost 90% contributing at 3 or 4 time points. Information on SARS-CoV-2 vaccination status was collected from participants, with the earliest reported vaccinations in the cohort occurring in May 2021.Main Outcome(s) and Measure(s) The main outcomes of this study were antibody responses to the SARS-CoV-2 spike protein as measured with a bead-based serologic assay. Individual-level outcomes were aggregated to population-level SARS-CoV-2 seroprevalence, attack rates, and boosting rates. Estimates were weighted by the local age distribution based on census data.Results By the end of the Delta wave and before widespread vaccination, nearly 70% of the study population had experienced SARS-CoV-2 infection. During the subsequent Omicron wave, 85% of unvaccinated, previously seronegative individuals were infected for the first time, and ∼50% or more of unvaccinated, already seropositive individuals were likely re-infected, leading to an overall 96% seropositivity in this population. Our results suggest a lower probability of re-infection in individuals with higher pre-existing antibody levels. We found evidence of household clustering of SARS-CoV-2 seroconversion. We found no significant associations between SARS-CoV-2 seroconversion and gender, household size, or recent Plasmodium falciparum malaria exposure.Conclusions and Relevance Findings from this study are consistent with very high infection rates and re-infection rates for SARS-CoV-2 in a rural population from eastern Uganda throughout the pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge sources of funding support, including from the Schmidt Science Fellows, in partnership with the Rhodes Trust (ST); Chan Zuckerberg Biohub Investigator program (IRB, BG); NIH/NIAID K23AI166009 (JB); NIH/NIAID U19AI089674 (JB, JR, MZ, TK, EA, MK, PJ, GD, BG, IS, IRB); NIH/NIAID U01AI150741 (ST, PJ, BG, IRB); K43TW010365 (JIN); NIH/NIGMS R35GM138361 (IRB).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Makerere University School of Medicine Research and Ethics Committee, the Uganda National Council of Science and Technology, the University of California, San Francisco, Human Research Protection Program, the London School of Hygiene & Tropical Medicine Ethics Committee, and the Stanford University Research Compliance Office. Written informed consent was obtained for all participants prior to study enrollment.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study will be made available at time of publication in a peer-reviewed journal, and are available upon reasonable request to the authors.